{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030485","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.069470+00:00","generated_at":"2026-06-08T14:29:42.756484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track","bullets":["Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.","Arimoclomol NDA resubmission for NPC on track by end of 2023; six-month FDA review expected if Type II.","Proposed Acer acquisition (OLPRUVA, EDSIVO) on track for Q4 close; Acer shareholder vote Nov 8, 2023.","Neil McFarlane named President and CEO effective Oct 10, 2023.","Cash $83.4M; cash runway into 2026 includes NDA resubmission and KP1077 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030485","json":"https://secwatch.observer/filing/0001437749-23-030485.json","markdown":"https://secwatch.observer/filing/0001437749-23-030485.md","text":"https://secwatch.observer/filing/0001437749-23-030485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/0001437749-23-030485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/zvra20230816_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:29:42.756484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d35551236cae21d7b229687e9813f3e4be95b992","claim":"ZEVRA THERAPEUTICS, INC. reported the quarter ended September 30, 2023 results: revenue Net revenue of $2.9M for Q3 2023.","evidence_excerpt":"er 2023 Financial Results Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra ’ s revenue with FDA-approved OLPRUVA ® for urea cycle disorders (UCDs) Net revenue of $2.9M for Q3 2023 Ended Q3 2023 with $83.4M in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 Conference call and live audio webcast scheduled for today, Nov 7, 2023, 8:00 a.m.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923030485/0001437749-23-030485-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"Net revenue of $2.9M for Q3 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}